Article (Published version) (547 Kb) - 
Free access
Highlights
Scientific Article
unige:82470 
 |
News in angiology and hemostasis |
|
| Authors | ||
| Published in | Revue médicale suisse. 2016, vol. 12, no. 500, p. 13-6 | |
| Abstract | This update describes contemporary studies of clinical relevance in angiology and hemostasis. We discuss newer developments for the treatment of haemophilia, with a focus on drugs with longer-half lives. Direct anticoagulants (DOAC: rivaroxaban, apixaban, edoxaban and dabigatran) and their approved prescription in Switzerland are summarized, with a description of antidotes that will be available in the near future. We will present new data on the utility of cancer screening at the diagnosis of idiopathic venous thromboembolism (VTE) and on the evaluation of DOAC in patients with cancer-related VTE. Finally, new studies evaluating the clinical risk-benefit of anticoagulation bridging for patients with vitamin K antagonists undergoing procedures do not support the use of such bridging in the majority of patients. | |
| Keywords | Anticoagulants/pharmacology/therapeutic use — Drug Approval — Hemophilia A/therapy — Hemostasis/drug effects — Humans — Switzerland — Vitamin K/antagonists & inhibitors | |
| Identifiers | PMID: 26946695 | |
| Full text | ||
| Structures | ||
| Research groups | Anatomie clinique (134) Geneva Platelet Group (13) La maladie thromboembolique veineuse (808) | |
| Citation (ISO format) | BOEHLEN, Françoise, BLONDON, Marc, FONTANA, Pierre. News in angiology and hemostasis. In: Revue médicale suisse, 2016, vol. 12, n° 500, p. 13-6. https://archive-ouverte.unige.ch/unige:82470 |
437 hits 
121 downloads 
Contact an author
Update